Lisa Ramazzotto
Papers
1
Total Citations
12
H-Index
1
About
Dr. Lisa Ramazzotto is a leading clinical researcher whose work centers on innovative treatments for neovascular age-related macular degeneration (nAMD), a primary cause of blindness. Her most significant contribution is her pivotal role in the STAR trial, a landmark, randomized, double-masked, sham-controlled device study published in 2024. This trial investigated stereotactic radiotherapy as a novel approach to mitigate the pathogenic processes underlying nAMD, aiming to reduce the burden of frequent anti-VEGF injections. By demonstrating the potential of ionizing radiation to complement or replace standard therapy, Dr. Ramazzotto’s work has opened new avenues for managing this blinding disease. Her research, which has garnered over a dozen citations in a short time, reflects a deep commitment to rigorous, evidence-based ophthalmology. Dr. Ramazzotto’s achievements underscore her as a key figure in advancing non-invasive, device-based interventions, offering hope for improved quality of life for patients with retinal disorders.
Research Focus
Key Achievements
Top Papers
- 1